Post-Exposure Prophylaxis (PEP) to Prevent HIV Infection

April 2023

Monitoring Test or Activity	Frequency	Notes
Clinic visit	Baseline48 hoursWeek 2Week 4Week 12	Follow-ups at 48 hours and 2 weeks may be conducted by telephone call.
HIV-1/2 antigen/antibody combination immunoassay (recommended even if the exposed individual declines PEP)	BaselineWeek 4Week 12	HIV specialist consultation: Immediate consultation with a clinician experienced in managing antiretroviral therapy is advised to determine optimal treatment options if the exposed individual's sequential test confirms HIV infection.
Serum liver enzymes, blood urea nitrogen, creatinine, CBC	 Baseline Weeks 12 and 24 in patients ≥12 years old 	 Obtain CBC in children 2 to 12 years old if PEP regimen contains zidovudine. Use a serum liver enzyme panel provided by laboratory. Repeat laboratory testing after week 2 of PEP medications in the case of abnormal renal or liver function [Mikati, et al. 2019]. Repeat laboratory testing if the patient experiences signs or symptoms of drug-induced kidney or liver injury while taking PEP medications.
Pregnancy test	Baseline Week 4	Only if exposed individual is of childbearing capacity.
HBsAg, anti-HBs	 Baseline: All patients Week 12: If patient is ≥12 years old 	Patients with a reactive anti-HBs test result need not repeat an HBsAg test.
HCV antibody	Baseline Week 24	If source patient has known HCV viremia or unknown status, HCV antibody testing should be performed at baseline as well as 24 weeks after an initial nonreactive test result.
HCV RNA	Week 4Week 12	If source patient has known HCV viremia or unknown status, HCV RNA should be performed during HIV testing at weeks 4 and 12.
RPR, 3-site screening for gonorrhea and chlamydia	Baseline	 Repeat screening at week 4 for sexual exposures. Repeat RPR at week 12 if the exposed individual is <12 years old.

Abbreviations: anti-HBs, hepatitis B surface antibody; CBC, complete blood count; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; PEP, post-exposure prophylaxis; RPR, rapid plasma reagin.

Reference

Mikati T, Crawley A, Daskalakis DC. Are routine renal and liver labs testing among PEP patients on TDF/FTC/DTV necessary? Abstract 983. CROI; 2019 Mar 4-7; Seattle, WA. https://www.croiconference.org/sessions/are-routine-renal-and-liver-labs-testing-among-pep-patients-tdfftcdtv-necessary